In lung cancer specifically, gedatolisib (a dual inhibitor of PI3K and mTOR) is being tested in a phase I trial in combination with the CDK4/6 inhibitor palbociclib in NSCLC (NCT03065062). The gene discussed is PIK3CA; the disease is lung carcinoma.